124 related articles for article (PubMed ID: 8911668)
21. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
[TBL] [Abstract][Full Text] [Related]
22. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Graham WC; Sambrook MA; Crossman AR
Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
[TBL] [Abstract][Full Text] [Related]
23. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Grondin R; Bédard PJ; Britton DR; Shiosaki K
Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
[TBL] [Abstract][Full Text] [Related]
24. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
25. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
27. Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Kashihara K; Manabe Y; Murakami T; Abe K
Life Sci; 2002 Jan; 70(9):1095-100. PubMed ID: 11860157
[TBL] [Abstract][Full Text] [Related]
28. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
29. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
[TBL] [Abstract][Full Text] [Related]
30. Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
Jourdain VA; Morin N; Morissette M; Grégoire L; Di Paolo T
Exp Neurol; 2014 Nov; 261():816-25. PubMed ID: 25172808
[TBL] [Abstract][Full Text] [Related]
31. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
32. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Larramendy C; Taravini IR; Saborido MD; Ferrario JE; Murer MG; Gershanik OS
Behav Brain Res; 2008 Dec; 194(1):44-51. PubMed ID: 18638507
[TBL] [Abstract][Full Text] [Related]
33. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
34. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Fariello RG
Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
[TBL] [Abstract][Full Text] [Related]
36. Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Arai N; Isaji M; Kojima M; Mizuta E; Kuno S
J Neural Transm (Vienna); 1996; 103(11):1307-16. PubMed ID: 9013417
[TBL] [Abstract][Full Text] [Related]
37. Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets.
Nomoto M; Kita S; Iwata SI; Kaseda S; Fukuda T
Pharmacol Biochem Behav; 1998 Mar; 59(3):717-21. PubMed ID: 9512077
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
39. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Boraud T; Bezard E; Bioulac B; Gross CE
Brain; 2001 Mar; 124(Pt 3):546-57. PubMed ID: 11222455
[TBL] [Abstract][Full Text] [Related]
40. Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.
Miyagi M; Arai N; Taya F; Itoh F; Komatsu Y; Kojima M; Isaji M
Biol Pharm Bull; 1996 Nov; 19(11):1499-502. PubMed ID: 8951172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
